FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 30 filers reported holding FUSION PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,119,202 | -44.3% | 3,122,770 | 0.0% | 0.17% | -34.8% |
| Q2 2023 | $14,583,336 | +23.9% | 3,122,770 | 0.0% | 0.26% | +14.3% |
| Q1 2023 | $11,772,843 | +15.9% | 3,122,770 | -3.2% | 0.23% | +19.1% |
| Q4 2022 | $10,158,026 | +4.6% | 3,224,770 | 0.0% | 0.19% | +7.8% |
| Q3 2022 | $9,707,000 | +20.9% | 3,224,770 | 0.0% | 0.18% | +23.3% |
| Q2 2022 | $8,030,000 | -68.0% | 3,224,770 | 0.0% | 0.15% | -64.0% |
| Q1 2022 | $25,056,000 | +86.3% | 3,224,770 | 0.0% | 0.41% | +134.7% |
| Q4 2021 | $13,447,000 | -47.3% | 3,224,770 | 0.0% | 0.17% | -38.4% |
| Q3 2021 | $25,540,000 | -2.0% | 3,224,770 | 0.0% | 0.28% | +6.4% |
| Q2 2021 | $26,056,000 | -24.6% | 3,224,770 | 0.0% | 0.26% | -18.3% |
| Q1 2021 | $34,570,000 | -8.8% | 3,224,770 | 0.0% | 0.32% | -2.7% |
| Q4 2020 | $37,891,000 | -2.2% | 3,224,770 | 0.0% | 0.33% | -31.8% |
| Q3 2020 | $38,762,000 | -31.2% | 3,224,770 | 0.0% | 0.49% | -38.6% |
| Q2 2020 | $56,337,000 | – | 3,224,770 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,543,342 | 3.52% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,664,303 | 2.68% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $4,058,553 | 1.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,354,258 | $3,521,071 | 0.64% |
| Avidity Partners Management LP | 5,781,850 | $15,032,810 | 0.60% |
| Eagle Health Investments LP | 579,769 | $1,507,399 | 0.33% |
| Perceptive Advisors | 2,751,395 | $7,153,627 | 0.24% |
| Ghost Tree Capital, LLC | 243,287 | $632,546 | 0.21% |
| Sio Capital Management, LLC | 246,036 | $639,694 | 0.20% |
| Artal Group S.A. | 1,725,000 | $4,485 | 0.19% |